641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H
| Autor: | de Bono, J.S., Shore, N.D., Kramer, G., Joshua, A.M., Li, X.T., Poehlein, C.H., Schloss, C., Yu, E.Y. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S670-S671 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|